NXTM

NexstimHLSE:NXTMH Stock Report

Market Cap

€31.5m

7D

-2.7%

1Y

21.4%

Updated

18 Sep, 2021

Data

Company Financials +
NXTMH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NXTMH Overview

Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.

Nexstim Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nexstim
Historical stock prices
Current Share Price€4.71
52 Week High€3.10
52 Week Low€12.30
Beta2.25
1 Month Change-13.10%
3 Month Change9.94%
1 Year Change21.39%
3 Year Change-96.76%
5 Year Change-99.63%
Change since IPO-99.98%

Recent News & Updates

Aug 18
Is Nexstim (HEL:NXTMH) Using Debt In A Risky Way?

Is Nexstim (HEL:NXTMH) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

NXTMHFI Medical EquipmentFI Market
7D-2.7%-0.9%-4.2%
1Y21.4%39.4%19.8%

Return vs Industry: NXTMH underperformed the Finnish Medical Equipment industry which returned 39.4% over the past year.

Return vs Market: NXTMH exceeded the Finnish Market which returned 19.8% over the past year.

Price Volatility

Is NXTMH's price volatile compared to industry and market?
NXTMH volatility
NXTMH Beta2.25
Industry Beta0.59
Market Beta1

Stable Share Price: NXTMH is more volatile than 90% of Finnish stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NXTMH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Finnish stocks.

About the Company

FoundedEmployeesCEOWebsite
200034Mikko Karvinenhttps://www.nexstim.com

Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression order or chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain.

Valuation

Is Nexstim undervalued compared to its fair value and its price relative to the market?

8.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NXTMH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NXTMH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NXTMH is unprofitable, so we can't compare its PE Ratio to the European Medical Equipment industry average.

PE vs Market: NXTMH is unprofitable, so we can't compare its PE Ratio to the Finnish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NXTMH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NXTMH is overvalued based on its PB Ratio (8.3x) compared to the XE Medical Equipment industry average (5.1x).


Future Growth

How is Nexstim forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

61.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXTMH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NXTMH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NXTMH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NXTMH's revenue (35.6% per year) is forecast to grow faster than the Finnish market (3.7% per year).

High Growth Revenue: NXTMH's revenue (35.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NXTMH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nexstim performed over the past 5 years?

12.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NXTMH is currently unprofitable.

Growing Profit Margin: NXTMH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NXTMH is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare NXTMH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXTMH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (59.7%).


Return on Equity

High ROE: NXTMH has a negative Return on Equity (-102.69%), as it is currently unprofitable.


Financial Health

How is Nexstim's financial position?


Financial Position Analysis

Short Term Liabilities: NXTMH's short term assets (€9.5M) exceed its short term liabilities (€3.0M).

Long Term Liabilities: NXTMH's short term assets (€9.5M) exceed its long term liabilities (€3.9M).


Debt to Equity History and Analysis

Debt Level: NXTMH's debt to equity ratio (116.1%) is considered high.

Reducing Debt: NXTMH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NXTMH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NXTMH has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 14.9% each year.


Dividend

What is Nexstim current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXTMH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXTMH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXTMH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXTMH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NXTMH's dividend in 3 years as they are not forecast to pay a notable one for the Finnish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Mikko Karvinen (45 yo)

1.58yrs

Tenure

Mr. Mikko Karvinen, M.Sc. (Econ.), serves as Chief Executive Officer at Nexstim Plc since June 16, 2020 and also served as an Interim Chief Executive Officer at Nexstim Plc since February 11, 2020 until Ju...


Leadership Team

Experienced Management: NXTMH's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: NXTMH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.1%.


Top Shareholders

Company Information

Nexstim Plc's employee growth, exchange listings and data sources


Key Information

  • Name: Nexstim Plc
  • Ticker: NXTMH
  • Exchange: HLSE
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €31.494m
  • Shares outstanding: 6.69m
  • Website: https://www.nexstim.com

Number of Employees


Location

  • Nexstim Plc
  • Elimäenkatu 9 B
  • Helsinki
  • Uusimaa
  • 510
  • Finland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 17:38
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.